Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326240 | 0.88 | NOTUM (0.55) | RAB9ANPC1TP53THRBMAPK1 | |
| SCHEMBL11902664 | 0.81 | NPC1 (0.51) | RAB9ANPC1TP53THRBMAPK1 | |
| SCHEMBL189929 | 0.81 | RAB9A (0.55) | RAB9ANPC1ALDH1A1POLBMAPT | |
| SCHEMBL2967412 | 0.81 | RAB9A (0.42) | RAB9ANPC1TP53MAPK1ALDH1A1 | |
| SCHEMBL4627994 | 0.81 | PTPN1 (0.41) | RAB9ANPC1TP53ALDH1A1MAPT | |
| SCHEMBL14138588 | 0.81 | HSD17B1 (0.56) | RAB9ANPC1TP53MAPK1ALDH1A1 | |
| SCHEMBL2489301 | 0.80 | RAB9A (0.50) | RAB9ANPC1TP53THRBMAPK1 | |
| Hydrochloric Acid SCHEMBL28551086 | 0.80 | RAB9A (0.53) | RAB9ANPC1ALDH1A1POLBMAPT | |
| SCHEMBL16825991 | 0.75 | NPC1 (0.50) | RAB9ANPC1TP53THRBMAPK1 | |
| SCHEMBL8375633 | 0.75 | RAB9A (0.54) | RAB9ANPC1TP53THRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772235-B2 | mGluR5 modulators | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7772235-B2 | mGluR5 modulators | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7772235-B2 | mGluR5 modulators | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7476684-B2 | Compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| US-7476684-B2 | Compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| US-7476684-B2 | Compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| CN-101273037-A | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | CN | disclosed |
| US-20080227824-A1 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227824-A1 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227824-A1 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20070270468-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270468-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| WO-2007040982-A1 | 5- (PHENYLISOXAZOLYLETHOXY) -TRIAZOL- 3 -YL SUBSTITUTED PYRIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040982-A1 | 5- (PHENYLISOXAZOLYLETHOXY) -TRIAZOL- 3 -YL SUBSTITUTED PYRIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | GRIN2C, OPRL1, GRIN2A | RAB9A 1050/4885NPC1 507/4885TP53 4844/4885 |
| US-20080227824-A1 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders | GRIN2C, GRIK5, GRIN3A | RAB9A 1954/4885NPC1 852/4885TP53 4823/4885 |
| US-20070270468-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | GRIN2C, OPRL1, GRIN2A | RAB9A 1050/4885NPC1 507/4885TP53 4844/4885 |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | GRIN2C, OPRL1, GRIN2A | RAB9A 1050/4885NPC1 507/4885TP53 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.